8-K: Assertio Holdings Reports Mixed Q1 2024 Results: Rolvedon Sales Surge, Indocin Declines Amidst Generic Competition

Assertio Holdings reported a mixed first quarter of 2024, with strong growth in Rolvedon sales offset by a decline in Indocin sales due to generic competition.

Summary

• Assertio Holdings announced its financial results for the first quarter of 2024, showing a mix of positive and negative trends.
• Net product sales were $31.9 million, a decrease from $41.8 million in the same quarter of the previous year, but slightly down from $32.5 million in the previous quarter.
• Rolvedon net product sales increased to $14.5 million, up from $11.0 million in the previous quarter, marking its fifth consecutive quarter of growth.
• Indocin net product sales decreased to $8.7 million, down from $10.8 million in the previous quarter, due to generic competition.
• The company reported a net loss of $4.5 million, compared to a net loss of $3.5 million in the first quarter of 2023.
• Adjusted EBITDA was $7.4 million, an increase from $4.5 million in the previous quarter, primarily due to lower SG&A expenses.
• Cash flow from operations was $7.5 million, and the company's cash balance reached $80.7 million.
• Assertio reiterated its full-year 2024 guidance, projecting net product sales between $110 million and $125 million and adjusted EBITDA between $20 million and $30 million.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to mixed results. While Rolvedon sales are growing and the company is managing costs, the decline in Indocin sales and the net loss are concerning. The reiteration of guidance provides some stability, but the risks remain significant.

Positives

• Rolvedon sales continue to grow, demonstrating strong market acceptance.
• The completion of enrollment in the Rolvedon same-day dosing trial could provide a competitive advantage.
• The company has successfully reduced SG&A expenses, leading to improved adjusted EBITDA.
• Assertio generated positive cash flow from operations and increased its cash balance.
• The company has reiterated its full-year guidance, indicating confidence in its future performance.

Negatives

• Net product sales decreased compared to the same quarter last year.
• Indocin sales declined due to generic competition, impacting overall revenue.
• The company reported a net loss for the quarter.
• Gross margin was impacted by amortization of Rolvedon purchase accounting inventory step-up.

Risks

• The company faces risks related to generic competition for its products, particularly Indocin.
• There are risks associated with the commercial success and market acceptance of Rolvedon.
• The company's ability to execute its sales and marketing strategies is crucial for future growth.
• The company is subject to litigation and government investigations, which could impact its financial results.
• The company's stock price has been trading near the Nasdaq minimum bid requirement, posing a risk of delisting.
• The company relies on single-source suppliers, which could disrupt its supply chain.

Future Outlook

Assertio has reiterated its 2024 full-year guidance, projecting net product sales between $110 million and $125 million and adjusted EBITDA between $20 million and $30 million. The company also expects data from the Rolvedon same-day dosing trial by year-end.

Management Comments

• We are pleased to report a strong first quarter as our team continues to diligently execute our business plan and seeks to grow Assertio for the benefit of our stockholders, said Heather Mason, interim Chief Executive Officer.
• We remain committed to our lean promotion platform and steadfast in our business development efforts as we work to secure additional new assets to fuel both sales growth and incremental cash flow generation.
• We are reiterating our guidance for 2024, calling for net product sales of $110 million to $125 million and adjusted EBITDA of $20 million to $30 million, concluded Mason.

Industry Context

The pharmaceutical industry is facing increasing generic competition, which is impacting the sales of established products like Indocin. Companies are focusing on new product launches and cost management to maintain profitability. Assertio's focus on Rolvedon and business development aligns with these industry trends.

Comparison to Industry Standards

• Assertio's performance is mixed when compared to industry standards.
• While Rolvedon's growth is a positive sign, the decline in Indocin sales due to generic competition is a common challenge faced by pharmaceutical companies with older products.
• Companies like Teva and Mylan, which focus on generic drugs, often see increased sales when generics are launched, while companies like Assertio that rely on branded products face revenue declines.
• The company's adjusted EBITDA of $7.4 million is relatively low compared to larger pharmaceutical companies, but it is an improvement from the previous quarter.
• The company's cash position of $80.7 million is moderate, and it will need to manage its cash flow carefully to fund future growth and acquisitions.
• The company's gross margin of 65% is lower than some of its peers, but this is impacted by the amortization of Rolvedon purchase accounting inventory step-up.

Legal Proceedings

• The company is involved in various litigation and government investigations, including those related to the Spectrum Merger, generic indomethacin suppositories, antitrust matters, and opioid-related issues.

Stakeholder Impact

• Shareholders may be concerned about the net loss and the decline in Indocin sales.
• Employees may be affected by the company's cost-cutting measures.
• Customers may benefit from the continued availability of Rolvedon.
• Suppliers may be impacted by the company's efforts to manage its supply chain.
• Creditors may be monitoring the company's financial performance and debt levels.

Next Steps

• The company will continue to focus on growing Rolvedon sales and market penetration.
• The company will await the data readout from the Rolvedon same-day dosing trial by year-end.
• The company will continue its business development efforts to acquire new assets.
• The company will host a conference call to discuss the results.

Key Dates

Keywords

pharmaceutical, Rolvedon, Indocin, net product sales, EBITDA, generic competition, financial results, cash flow, SG&A, market penetration